Regeneron exceeds profit expectations thanks to strong Dupixent sales.

Regeneron Pharmaceuticals Inc Beats Wall Street Estimates with Strong Demand for Dupixent

Regeneron Pharmaceuticals Inc has exceeded Wall Street expectations for first-quarter profit, thanks to the high demand for eczema treatment Dupixent. The quarterly sales of Dupixent, which are recorded by Regeneron’s partner Sanofi, rose by approximately 37% to $2.49 billion. This figure is higher than the $2.38 billion that analysts had predicted, according to an average of six analysts’ estimates polled by Refinitiv.

Impressive Revenue Figures

Regeneron’s total revenue of $3.16 billion also surpassed expectations of $3 billion in the quarter. Excluding items, the company reported a profit of $10.09 per share, which is above the estimated $9.56.

Positive Outlook for Regeneron

These impressive figures are a testament to the success of Regeneron’s Dupixent treatment. The company’s strong financial performance is expected to continue, with Dupixent’s sales predicted to rise even further in the coming months.

Meet the CEOs of Top AI Companies

In other news, the White House is set to host CEOs of top artificial intelligence companies, including Alphabet Inc’s Google and more. This event is a testament to the growing importance of AI in the tech industry and beyond.

Other Top Stories:

• Impact Nano, a Massachusetts-based startup that makes specialty chemicals for the semiconductor industry
• Sberbank, Russia’s dominant lender, has become one of the country’s leading technology players
• France’s antitrust watchdog has given Facebook-owner Meta two months to change its access rules for ad verification partners

Stay up-to-date with the latest news and trends in the tech industry with Reuters.

*As an Amazon Associate I earn from qualifying purchases